Table 1.
Descriptive characteristicsa
| COVID-19 negative N = 8628 |
COVID-19 positive N = 5636 |
Total N = 14,264 |
|
|---|---|---|---|
| Enrollmentb | |||
| Prospective | 4033 (47%) | 4555 (81%) | 8588 (60%) |
| Retrospective | 4595 (53%) | 1081 (19%) | 5676 (40%) |
| Prospective enrollees | |||
| Follow-up data | 243 (6.0%) | 167 (3.7%) | 410 (4.8%) |
| Weeks past LMP at enrollment (median (IQR)) | 27 (18, 35) | 25 (17, 33) | 26 (17, 34) |
| Weeks past LMP at symptom onset/test (median (IQR)) | 21 (12, 30) | 19 (10, 27) | 20 (11, 28) |
| Weeks past LMP at delivery or end of follow-up (median (IQR)) | 28 (12, 36) | 26 (17, 33) | 27 (18, 35) |
| Retrospective enrollees | |||
| Follow-up data | 4449 (97%) | 1025 (95%) | 5474 (96%) |
| Weeks past LMP at enrollment (median (IQR)) | 49 (44, 54) | 47 (43, 53) | 49 (44, 54) |
| Weeks past LMP at symptom onset/test (median (IQR)) | 38 (37, 39) | 34 (28, 38) | 38.0 (35.4, 39.3) |
| Weeks past LMP at delivery or end of follow-up (median (IQR)) | 39 (38, 40) | 39 (38, 40) | 39 (38, 40) |
| COVID-19 severity | |||
| Negative | 8628 (100%) | 8628 (60%) | |
| Asymptomatic | 577 (10%) | 577 (4.0%) | |
| Mild | 2104 (37%) | 2104 (15%) | |
| Moderate | 2662 (47%) | 2662 (19%) | |
| Severe | 293 (5.2%) | 293 (2.1%) | |
| COVID-19 diagnosis/test type | |||
| Negative | 8628 (100%) | 8628 (60%) | |
| Positive by antibodies only | 531 (9.4%) | 531 (3.7%) | |
| Positive by throat/nose swab | 4486 (80%) | 4486 (31%) | |
| Positive clinically only | 619 (11%) | 619 (4.3%) | |
| Reason for COVID-19 test | |||
| Symptoms | 1234 (14%) | 4082 (72%) | 5316 (37%) |
| Contact tracing/risk zone travel | 1703 (20%) | 972 (17%) | 2675 (19%) |
| Surveillance (healthy) | 2460 (29%) | 224 (4.0%) | 2684 (19%) |
| Other/none | 3230 (37%) | 357 (6.3%) | 3587 (25%) |
| Age | 31.0 (27.0, 34.0) | 30.0 (27.0, 34.0) | 31.0 (27.0, 34.0) |
| Healthcare coverage | 6686 (89%) | 3702 (85%) | 10,388 (87%) |
| Pre-existing condition | 1112 (15%) | 482 (12%) | 1594 (14%) |
| Primiparous | 3364 (46%) | 1699 (42%) | 5063 (44%) |
| Pre-pregnancy BMI (kg/m2) | |||
| < 25 | 3218 (47%) | 1782 (48%) | 5000 (47%) |
| 25–30 | 1775 (26%) | 1023 (28%) | 2798 (27%) |
| > = 30 | 1849 (27%) | 902 (24%) | 2751 (26%) |
| Continent | |||
| Africa | 378 (4.4%) | 238 (4.2%) | 616 (4.3%) |
| Asia | 489 (5.7%) | 413 (7.3%) | 902 (6.3%) |
| Europe | 3084 (36%) | 1310 (23%) | 4394 (31%) |
| North America | 3328 (39%) | 1601 (28%) | 4929 (35%) |
| South America | 1347 (16%) | 2073 (37%) | 3420 (24%) |
aDescriptive characteristics of eligible participants in the International Registry of Coronavirus Exposure in Pregnancy who enrolled between June 2020 and July 2021 (n = 14,264)
bProspective enrollment occurred during pregnancy, and retrospective enrollment during the 6 months after the end of pregnancy
COVID-19 Coronavirus disease 2019, LMP Last menstrual period, BMI Body mass index